1Farenc C, Fabreguette JR, Bressolle F. Pk-fit: a pharmacokinetic/pharmacodynamic and statistical data analysis software[J]. Comput Biomed Res, 2000, 33(5) :315 - 329.
2Jonsson EN, Wade JR, Karlsson MO. Comparison of some practical sampling strategies for population pharmacokintic studies[J]. J Pharmacokinet Biopharm, 1996, 24(2):245-263.
3Ette EI. Stability and performance of a population pharmacokinetic model[J]. J Clin Pharmacol, 1997, 37(6):486 - 495.
4Breilh D, Saux MC, Maire P, et al. Mixed pharmacokine tic population study and diffusion model to describe ciprofloxacin lung concentrations [J]. Comput Biol Med,2001, 31(3):147- 155.
5Breilh D, Saux MC, Delaisement C, et al. Pharmacokinetic population study to describe cefepime lung concentrations [J]. Pulm Pharmacol Ther, 2001, 14(2) :69- 74.
6Green B, Duffull SB. Prospective evaluation of a D-optimal designed population pharmacokinetic study[J]. J Pharmacokinet Pharmacodyn, 2003, 30(2): 145 - 161.
7Ragueneau I, Laveille C, Jochemsen R, et al. Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine , a direct sinus node inhibitor, on heart rate in healthy volunteers[J]. Clin Pharmacol Ther, 1998, 64(2): 192 -203.
8Furuya A, Kato N, Jingu S, et al. Population pharmcokinetics and pharmcodynamics of TS-943 for selective nonpeptide platelet glycoprotein Ⅱ b/Ⅲ a receptor antagonist in normal healthy subjects [J]. Clin Pharmacol Ther, 2000,67(5) :489 - 497.
9Wang B, Ludden TM, Cheung EN, et al. Population pharmacokinetic-pharmacodynamic modeling of filgrastim (rmetHuG-CSF) in healthy volunteers[J]. J Pharmacokinet Pharmacodyn, 2001, 28(4):321-342.
10Blesch KS, Gieschke R, Tsukamoto y, et al. Clinical pharmacokinetic/pharmacodynamic and physiologically based pharmacokinetic modeling in new drug development:the capecitabine experience[J]. Invest New Drugs, 2003,21(2): 195 - 223.
